EPISODE · Mar 10, 2026 · 1 MIN
Teclistamab–Daratumumab Approved for Relapsed/Refractory Myeloma
from TheBrief.Health · host TheBrief.Health
Long-term levothyroxine therapy in older adults may modestly reduce cardiovascular risk when carefully monitored, but clinicians must balance benefits with risks like atrial fibrillation and bone loss.
Embed this episode
NOW PLAYING
Teclistamab–Daratumumab Approved for Relapsed/Refractory Myeloma
0:00
1:40
1×
No transcript for this episode yet
Similar Episodes
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of TheBrief.Health?
This episode is 1 minute long.
When was this TheBrief.Health episode published?
This episode was published on March 10, 2026.
Can I download this TheBrief.Health episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!